- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04860765
COMPASSION S3 Post-Approval Study
March 12, 2024 updated by: Edwards Lifesciences
Congenital Multicenter Trial of Pulmonic Valve Dysfunction Studying the SAPIEN 3 Interventional THV Post-Approval Study
This study will monitor device performance and outcomes of the SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted surgical valve in the pulmonic position with a clinical indication for intervention.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a single arm, prospective, multicenter post-approval study.
Study Type
Observational
Enrollment (Estimated)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Edwards THV Clinical Affairs
- Phone Number: 949-250-2500
- Email: THV_CT.gov@Edwards.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35487
- Recruiting
- University Of Alabama
-
-
California
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars Sinai
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Children's Hospital of Colorado
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Withdrawn
- Emory University
-
-
Illinois
-
Oak Lawn, Illinois, United States, 60453
- Recruiting
- Advocate Childrens Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Children's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Recruiting
- Minneapolis Heart
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- St. Louis Children's Hospital
-
-
New Jersey
-
Newark, New Jersey, United States, 07112
- Recruiting
- Newark Beth Israel Medical Center
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center/NYPH
-
New York, New York, United States, 10029
- Recruiting
- Mount Sinai
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinatti Children's Hospital
-
Columbus, Ohio, United States, 43215
- Recruiting
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 19146
- Recruiting
- University of Pittsburgh Medical Center
-
-
Texas
-
Austin, Texas, United States, 78723
- Recruiting
- Dell Children's
-
Dallas, Texas, United States, 75235
- Recruiting
- Children's Health Dallas
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- Recruiting
- Primary Children's
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Recruiting
- University of Virginia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position with a clinical indication for intervention
Description
Inclusion Criteria:
- Dysfunctional RVOT conduit or previously implanted surgical valve
- RVOT/PV with ≥ moderate regurgitation and/or a mean RVOT/PV gradient of ≥ 35 mmHg
Exclusion Criteria:
- Inability to tolerate an anticoagulation/antiplatelet regimen
- Active bacterial endocarditis or other active infections
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
TPVR
Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
|
SAPIEN 3 THV in the pulmonic position
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device Success
Time Frame: Discharge, expected to be within 1-5 days post-procedure
|
Defined as a composite of:
|
Discharge, expected to be within 1-5 days post-procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 13, 2021
Primary Completion (Estimated)
August 1, 2030
Study Completion (Estimated)
August 1, 2030
Study Registration Dates
First Submitted
April 23, 2021
First Submitted That Met QC Criteria
April 23, 2021
First Posted (Actual)
April 27, 2021
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 12, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-07
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Valve Insufficiency
-
Charite University, Berlin, GermanyRecruitingPulmonary Regurgitation | Tricuspid RegurgitationGermany
-
Edwards LifesciencesCompletedPulmonary Regurgitation | Pulmonary Insufficiency | Pulmonary StenosisGermany, Ireland, Belgium, Israel, United Kingdom, Italy, Poland, Saudi Arabia, Turkey
-
Taewoong Medical Co., Ltd.Active, not recruitingPulmonary Valve Stenosis | Congenital Heart Defect | Pulmonary Valve; Insufficiency, CongenitalKorea, Republic of
-
Edwards LifesciencesCompletedPulmonary Valve Insufficiency | Pulmonary Valve Degeneration | Congenital Pulmonary Valve AbnormalityUnited States
-
Venus MedTech (HangZhou) Inc.IQVIA Inc.; TheraGenesis; IntrialsActive, not recruiting
-
CryoLife, Inc.CompletedAortic Valve Stenosis | Aortic Valve Insufficiency | Pulmonary Valve Insufficiency | Pulmonary Valve StenosisUnited States
-
Venus MedTech (HangZhou) Inc.Not yet recruitingPulmonary Regurgitation
-
CSD Labs GmbHCompletedAortic Stenosis | Mitral Insufficiency | Tricuspid Regurgitation | Aortic Insufficiency | Mitral Insufficiency and Aortic Stenosis | Insufficiency, Pulmonary | Insufficiency, TricuspidAustria
-
Assistance Publique - Hôpitaux de ParisEuropean Georges Pompidou Hospital; Hôpital Necker-Enfants MaladesCompletedPulmonary Valve InsufficiencyFrance
-
Edwards LifesciencesCompletedPulmonary Valve Insufficiency | Pulmonary Regurgitation | Pulmonary Stenosis | Dysfunctional RVOT Conduit | Pulmonary ObstructionUnited States
Clinical Trials on SAPIEN 3 THV
-
Edwards LifesciencesRecruitingPulmonary Valve Insufficiency | Complex Congenital Heart Defect | Dysfunctional RVOT Conduit | Pulmonary Valve DegenerationUnited States
-
Edwards LifesciencesActive, not recruitingHeart Diseases | Aortic Stenosis, SevereUnited States, Canada
-
Edwards LifesciencesRecruitingAortic Stenosis | Aortic Stenosis, SevereUnited States, Canada
-
Edwards LifesciencesActive, not recruitingAortic StenosisUnited States, Australia, Japan, Canada, New Zealand
-
Edwards LifesciencesActive, not recruitingAortic Valve StenosisCanada, United Kingdom
-
Edwards LifesciencesActive, not recruitingTetralogy of Fallot | Pulmonary Disease | Congenital Heart Disease | Pulmonary Regurgitation | Transcatheter Pulmonary Valve Replacement (TPVR)United States
-
Cardiovascular Research Foundation, New YorkCardialysis BV; AvaniaActive, not recruitingAortic Valve StenosisUnited States, Canada, Netherlands
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Edwards LifesciencesNot yet recruitingMitral Regurgitation | Mitral Valve Disease | Mitral Stenosis
-
Meril Life Sciences Pvt. Ltd.RecruitingAortic Valve StenosisSweden, Hungary, France, Belarus, Croatia, Germany, Netherlands, New Zealand, Poland, Portugal, Slovakia, Slovenia, Spain, Italy, Brazil, Estonia, Greece